Vasomune Therapeutics Appoints Meenu Chhabra to its Board of Directors Industry Leader Joins Vasomune’s Board of Directors as the Company Transitions to Clinical Development of AV-001 for the treatment of COVID-19/Pathogen-induced…
An article in USA Today describes certain risks associated with contraction of the COVID-19 coronavirus, specifically the major cause of lethality being Acute Respiratory Distress Syndrome (ARDS). The article can…
Vasomune Therapeutics is a private biotechnology company developing the next generation of medications to harness the body’s ability to defend against illness by modifying the host vascular endothelial response.